Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bodal Chemicals Limited (BODALCHEM.NS)
Ahmedabad, IN
Bodal Chemicals Limited, an Indian enterprise, produces and supplies a range of chemicals, including dyestuffs, dye intermediates, and various other chemical products. Its comprehensive portfolio of dye intermediates features key compounds such as vinyl sulphone ester, H. acid, Bronner's vinyl sulphone, meta ureido aniline, and gamma acid, alongside numerous other specialized chemicals. The company also furnishes reactive, acid, and direct dyes for the textile, leather, and paper industries. Additionally, it manufactures essential raw materials crucial for dye intermediate production, such as sulphuric acid, chloro sulphonic acid, liquid SO3, oleums, beta napthol, and linear alkyl benzene sulphonic acid. Bodal Chemicals Limited is also an exporter of its products. Incorporated in 1986 and headquartered in Ahmedabad, India, the company was formerly named Dintex Dyechem Limited before changing to its current appellation in May 2006.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.28% | +11.73% | +13.51% | +62.59% | +40.55% | +41.39% | -0.72% | +14.24% | -25.54% | -11.76% | +175.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+15.3% ★ Q1'26: +30.4% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+158.5% ★ Q1'26: +121.7% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+2.4% Q1'26: +10.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+4.9% Q1'26: +9.2% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+4.5% Q1'26: +9.8% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-0.1% Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×4.84× Q1'26: 2.85× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.36B
est: 9.92B (+4.4%)
|
9.10B
est: 9.06B (+0.5%)
|
12.36B
est: 11.66B (+6.0%)
|
11.30B
est: 11.97B (-5.6%)
|
13.99B
est: 14.24B (-1.8%)
|
13.62B
est: 13.39B (+1.7%)
|
12.21B
est: 11.58B (+5.5%)
|
20.27B
est: 18.66B (+8.6%)
|
15.63B
est: 15.30B (+2.2%)
|
13.95B
est: 13.95B (0.0%)
|
17.45B
est: 17.01B (+2.6%)
|
20.01B
20.01B – 20.01B
+17.6% YoY
|
22.23B
22.23B – 22.23B
+11.1% YoY
|
| EBITDA |
1.89B
est: 920.80M (+105.0%)
|
1.69B
est: 840.87M (+100.4%)
|
2.41B
est: 1.08B (+123.0%)
|
2.04B
est: 1.11B (+83.5%)
|
2.47B
est: 1.32B (+86.7%)
|
1.45B
est: 1.24B (+16.8%)
|
1.00B
est: 1.04B (-3.5%)
|
2.16B
est: 1.36B (+58.8%)
|
1.45B
est: 1.46B (-0.6%)
|
1.19B
est: 1.30B (-7.7%)
|
1.69B
est: 1.58B (+6.9%)
|
1.86B
1.86B – 1.86B
+17.6% YoY
|
2.07B
2.07B – 2.07B
+11.1% YoY
|
| EBIT |
1.65B
est: 594.34M (+177.9%)
|
1.43B
est: 542.74M (+163.0%)
|
2.11B
est: 698.61M (+201.7%)
|
1.90B
est: 717.33M (+164.9%)
|
2.26B
est: 853.21M (+164.4%)
|
1.17B
est: 802.19M (+45.5%)
|
697.14M
est: 998.90M (-30.2%)
|
1.70B
est: 1.31B (+29.5%)
|
918.61M
est: 1.40B (-34.5%)
|
589.81M
est: 835.87M (-29.4%)
|
1.01B
est: 991.86M (+1.7%)
|
1.17B
1.17B – 1.17B
+17.6% YoY
|
1.30B
1.30B – 1.30B
+11.1% YoY
|
| Net Income |
917.82M
est: 1.08B (-15.3%)
|
859.87M
est: 919.29M (-6.5%)
|
1.29B
est: 1.34B (-4.2%)
|
1.23B
est: 1.24B (-0.8%)
|
1.43B
est: 1.62B (-11.4%)
|
871.64M
est: 1.24B (-29.7%)
|
419.82M
est: 719.70M (-41.7%)
|
1.04B
est: 943.24M (+10.5%)
|
380.33M
est: 1.01B (-62.3%)
|
64.69M
est: 75.56M (-14.4%)
|
185.02M
est: 125.86M (+47.0%)
|
578.97M
578.97M – 578.97M
+360.0% YoY
|
893.63M
893.63M – 893.63M
+54.3% YoY
|
| SGA |
494.62M
est: 943.14M (-47.6%)
|
113.31M
est: 861.27M (-86.8%)
|
122.91M
est: 1.11B (-88.9%)
|
138.63M
est: 1.14B (-87.8%)
|
166.31M
est: 1.35B (-87.7%)
|
249.68M
est: 1.27B (-80.4%)
|
205.97M
est: 1.84B (-88.8%)
|
1.12B
est: 2.42B (-53.6%)
|
962.12M
est: 2.59B (-62.8%)
|
154.49M
est: 1.33B (-88.4%)
|
5.77B
est: 2.58B (+123.3%)
|
3.04B
3.04B – 3.04B
+17.6% YoY
|
3.38B
3.38B – 3.38B
+11.1% YoY
|
| EPS |
8.41
est: 8.60 (-2.2%)
|
7.88
est: 7.30 (+7.9%)
|
12.18
est: 10.66 (+14.2%)
|
10.67
est: 9.81 (+8.8%)
|
11.72
est: 12.84 (-8.7%)
|
7.13
est: 9.85 (-27.6%)
|
3.43
est: 6.30 (-45.6%)
|
8.30
est: 9.30 (-10.8%)
|
3.03
est: 2.60 (+16.5%)
|
0.51
est: 0.60 (-15.0%)
|
1.47
est: 1.00 (+47.0%)
|
4.60
4.60 – 4.60
+360.0% YoY
|
7.10
7.10 – 7.10
+54.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-25 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sureshbhai Jayantibhai Patel | Chairman, MD & Chief Executive Officer | 16M | male |
| Bhavin Suresh Patel | Executive Director | 11M | male |
| Ankit Sureshbhai Patel | Executive Director | 11M | male |
| Mayur Bachubhai Padhya | Chief Financial Officer | 7M | male |
| Rajarshi Ghosh | Director of Health, Safety & Environment and Director | 3M | male |
| Ashutosh Bhatt | Company Secretary & Compliance Officer | 2M | male |
| Bansibhai Maganbhai Patel | President of Production & Technical | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BODALCHEM.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
